|143.41 1.02 (0.72%)||12-01 16:00|
|Targets||6-month :||170.18||1-year :||198.78|
|Resists||First :||145.71||Second :||170.18|
|Supports||First :||139.61||Second :||135.85|
|MAs||MA(5) :||140.29||MA(20) :||139.49|
|MA(100) :||145.97||MA(250) :||148.87|
|MACD||MACD :||-0.9||Signal :||-1.7|
|%K %D||K(14,3) :||73.2||D(3) :||52.9|
|52-week||High :||168.11||Low :||130.96|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ABBV ] has closed Bollinger Bands are 33.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||142.88 - 143.41||143.41 - 143.83|
|Low:||136.59 - 137.25||137.25 - 137.79|
|Close:||141.38 - 142.42||142.42 - 143.25|
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Thu, 30 Nov 2023
Why Abbvie Stock Popped Today - The Motley Fool
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||1,770 (M)|
|Shares Float||1,760 (M)|
|Held by Insiders||0.1 (%)|
|Held by Institutions||71.4 (%)|
|Shares Short||13,230 (K)|
|Shares Short P.Month||12,310 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||6.84|
|Profit Margin||11.8 %|
|Operating Margin||17.7 %|
|Return on Assets (ttm)||8.6 %|
|Return on Equity (ttm)||46.3 %|
|Qtrly Rev. Growth||-6 %|
|Gross Profit (p.s.)||23.46|
|Sales Per Share||31.15|
|Qtrly Earnings Growth||-54.8 %|
|Operating Cash Flow||25,510 (M)|
|Levered Free Cash Flow||24,070 (M)|
|Price to Book value||20.93|
|Price to Sales||4.6|
|Price to Cash Flow||9.94|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|